Pharmacogenomics Market Research Report – Global Forecast Till 2023

Pharmacogenomics Market Research Report, By Technology (Microarray, Sequencing, Polymerase Chain Reaction) By Application (Cardiology, Neurological Disorders) By End Users (Hospitals, Research Organizations, Academic Institute) - Global Forecast till 2023

Pharmacogenomics Market Overview

Global Pharmacogenomics Market is expected to grow at CAGR of 5.8% during the forecast period. Pharmacogenomics defines how genes can affect a person’s response to drugs. It is relatively a new field and combines pharmacology and genomics. The aim of pharmacogenomics is to develop effective and safe medications. Moreover by pharmacogenomics, drugs doses can be tailored to a person’s genetic makeup. The field of pharmacogenomics is predicted to treat a wide range of health problems including cardiovascular diseases, Alzheimer disease, cancer, HIV/AIDS, and asthma, in near future. According to the Organisation for Economic Co-operation and Development (2017), biotech R&D in the business enterprise sector was 11.3%, and 9.4% for U.S. and France respectively in 2014. Moreover, in 2016, according to the company BIOCOM AG, the total turnover for the Germany based biotech companies was USD 3.7 billion. The above data concludes that the biotechnology industry is expanding. This growing biotech sector along with the rising healthcare expenditures, and increasing interest for customized drugs will drive the pharmacogenomics market growth. However, lack of awareness and lack of consistency in pharmacogenomics products will restrain the pharmacogenomics market growth during the forecast period.

Pharmacogenomics Market Intended Audience

- Pharmaceutical companies
- Biotechnological institutes
- Government and Private Laboratories
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers

Figure 1:- Pharmacogenomics market share, by region
Pharmacogenomics Market Segmentation

The global pharmacogenomics market is segmented on the basis of technology, application, and end user.

On the basis of technology, the pharmacogenomics market is segmented into microarray, sequencing, polymerase chain reaction, and others. The sequencing segment is sub-segmented into Sanger sequencing, pyrosequencing, next-generation sequencing, and others. On the basis of application, the pharmacogenomics market is segmented into oncology, cardiology, neurological disorders, and others. The oncology segment, by technology, is sub-segmented into breast cancer, lung cancer, and others. On the basis of end users, the pharmacogenomics market is segmented into hospitals, research organizations, academic institute, and others.

Pharmacogenomics Market Regional Analysis

The Americas dominate the global pharmacogenomics market owing to a well-developed healthcare sector and presence of developed economies like the U.S. and Canada. Moreover, increasing number of patients suffering from cardiovascular diseases and rising healthcare expenditure have boosted the growth of the market in America. In 2016, according to the Centres for Diseases Control and Prevention in the U.S., heart disease was the leading cause of death for both men and women. Moreover, it was also estimated that the healthcare expenditure for heart diseases in the U.S. reaches USD 200 billion each year.

Europe is the second largest pharmacogenomics market, followed by Asia Pacific. Availability of funds for research and development along with government support and presence of huge patient population within the region will drive the market growth during the forecast period. Moreover, the presence of the developed economies like Germany and France within the region fuels the pharmacogenomics market growth.

Asia Pacific is the fastest growing region for the pharmacogenomics market due to the presence of a huge patient population, continuously developing economies like India and China and presence of huge opportunities in the market drives the pharmacogenomics market. According to the Indian Brand Equity Foundation in 2016, the Indian biotech industry is estimated to reach USD 100 billion by 2025 from USD 7 billion in 2015 with a CAGR of 30.46%.

On the other hand, the Middle East & Africa has the least share in the global pharmacogenomics market due to presence of poor economy, low per capita healthcare expenditure and stringent government policies especially in the Africa region. The majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. Moreover, developed economies like Dubai, Saudi Arabia, Dubai, besides others fuels the pharmacogenomics market growth within the Middle East & Africa region.

Research Methodology
Sources: WHO, annual reports, press release, white paper, and company presentation

Key players for Global Pharmacogenomics Market

The key players for the Global Pharmacogenomics Market are Myriad Genetics, Inc. (U.S.), 23andMe, Inc. (U.S.), Pathway Genomics (U.S.), GeneTech (U.S.), GeneDx. (U.S.), Future Science Group (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Assurex Health, Inc. (U.S.), and others.

Contents:

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Pharmacogenomics Market Introduction

2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations

Chapter 3. Pharmacogenomics Market: Research Methodology

3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Pharmacogenomics Market Size Estimation

Chapter 4. Pharmacogenomics Market Dynamics

4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment

Chapter 5. Pharmacogenomics Market Factor Analysis

5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

Chapter 6. Global Pharmacogenomics Market, by Technology
6.1 Introduction
6.2 Microarray
Market Estimates & Forecast, 2017 – 2023
6.3 Sequencing
Market Estimates & Forecast, 2017 – 2023
6.3.1 Sanger Sequencing
6.3.2 Pyrosequencing
6.3.3 Next-Generation Sequencing
6.3.4 Others
6.4 Polymerase Chain Reaction
Market Estimates & Forecast, 2017 – 2023
6.5 Others

Chapter 7. Global Pharmacogenomics Market, by Application
7.1 Introduction
7.2 Oncology
Market Estimates & Forecast, 2017 – 2023
7.2.1 Breast Cancer
7.2.2 Lung Cancer
7.2.3 Others
7.3 Cardiology
Market Estimates & Forecast, 2017 – 2023
7.4 Neurological Disorders
Market Estimates & Forecast, 2017 – 2023
7.5 Others
Market Estimates & Forecast, 2017 – 2023

Chapter 8 Global Pharmacogenomics Market, by End User
8.1 Introduction
8.2 Hospitals and clinics
Market Estimates & Forecast, 2017 – 2023
8.3 Research Organizations
Market Estimates & Forecast, 2017 – 2023
8.4 Academic Institute
Market Estimates & Forecast, 2017 – 2023
8.5 Others
Market Estimates & Forecast, 2017 – 2023

Chapter 9. Global Pharmacogenomics Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape: Pharmacogenomics Market
10.1 Introduction
10.2 Pharmacogenomics Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments

Chapter 11 Company Profiles
11.1 Myriad Genetics, Inc.
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.2 23andMe, Inc.
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Pathway Genomics
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 GeneTech
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 GeneDx.
11.5.1 Overview
11.5.2 Company Overview
11.5.3 Product Overview
11.5.4 Financial overview
11.5.5 Key Developments
11.6 Future Science Group
11.6.1 Overview
11.6.2 Company Overview
11.6.3 Product Overview
11.6.4 Financial Overview
11.6.5 Key Developments
11.7 Teva Pharmaceutical Industries Ltd.
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Assurex Health, Inc.
11.8.1 Overview
11.8.2 Product Overview
11.8.3 Financials
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.9 Others

Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Pharmaceutical industry

Chapter 13 Appendix

LIST OF TABLES
Table 1 Pharmacogenomics Industry Synopsis, 2017 – 2023
Table 2 Global Pharmacogenomics Market Estimates and Forecast, 2017 – 2023, (USD Million)
Table 3 Global Pharmacogenomics Market by Region, 2017 – 2023, (USD Million)
Table 4 Global Pharmacogenomics Market by Technology, 2017 – 2023, (USD Million)
Table 5 Global Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)
Table 6 Global Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)
Table 7 North America Pharmacogenomics Market by Technology, 2017 – 2023, (USD Million)
Table 8 North America Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)
Table 9 North America Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)
Table 10 US Pharmacogenomics Market by Technology, 2017 – 2023, (USD Million)
Table 11 US Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)
Table 12 US Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)
Table 13 Canada Pharmacogenomics Market by Technology, 2017 – 2023, (USD Million)
Table 14 Canada Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)
Table 15 Canada Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)
Table 16 South America Pharmacogenomics Market by Technology, 2017 – 2023, (USD Million)
Table 17 South America Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)
Table 18 South America Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)
Table 19 Europe Pharmacogenomics Market by Technology, 2017 – 2023, (USD Million)
Table 20 Europe Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)
Table 21 Europe Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)
Table 22 Western Europe Pharmacogenomics Market by Technology, 2017 – 2023, (USD Million)
Table 23 Western Europe Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)
Table 24 Western Europe Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)
Table 25 Eastern Europe Pharmacogenomics Market by Technology, 2017 – 2023, (USD Million)
Table 26 Eastern Europe Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)
Table 27 Eastern Europe Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)
Table 28 Asia Pacific Pharmacogenomics Market by Technology, 2017 – 2023, (USD Million)
Table 29 Asia Pacific Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)
Table 30 Asia Pacific Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)
Table 31 Middle East & Africa Pharmacogenomics Market by Technology, 2017 – 2023, (USD Million)
Table 32 Middle East & Africa Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)
Table 33 Middle East & Africa Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)

LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Pharmacogenomics Market
Figure 3 Segmentation Market Dynamics for Global Pharmacogenomics Market
Figure 4 Global Pharmacogenomics Market Share, by Technology 2016
Figure 5 Global Pharmacogenomics Market Share, by Application 2016
Figure 6 Global Pharmacogenomics Market Share, by End Users, 2016
Figure 7 Global Pharmacogenomics Market Share, by Region, 2016
Figure 8 North America Pharmacogenomics Market Share, by Country, 2016
Figure 9 Europe Pharmacogenomics Market Share, by Country, 2016
Figure 10 Asia Pacific Pharmacogenomics Market Share, by Country, 2016
Figure 11 Middle East & Africa Pharmacogenomics Market Share, by Country, 2016
Figure 12 Global Pharmacogenomics Market: Company Share Analysis, 2016 (%)
Figure 14 Myriad Genetics, Inc.: Key Financials
Figure 15 Myriad Genetics, Inc.: Segmental Revenue
Figure 16 Myriad Genetics, Inc.: Geographical Revenue
Figure 17 23andMe, Inc.: Key Financials
Figure 18 23andMe, Inc.: Segmental Revenue
Figure 19 23andMe, Inc.: Geographical Revenue
Figure 20 Pathway Genomics: Key Financials